CD8A and neoplasm: Additionally, flow cytometry and single-cell RNA-seq reveal that αPD-1-(iRGD)2 remodels the TME and expands “better effector” CD8+ T-cells with a hot tumor phenotype, expressing stem- and memory-associated genes, suggesting its potential as promising novel cancer immunotherapy [337].